Edesa Biotech Showcases Innovation at Investor Conference
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Edesa Biotech to Participate in Upcoming Investor Conferences
TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas
Edesa Biotech(EDSA.US) 10% Shareholder Buys US$20,000 in Common Stocks
$Edesa Biotech(EDSA.US)$ 10% Shareholder Nijhawan Pardeep purchased 5,000 shares of Common Stocks on Mar 25, 2024 at an average price of $4 for a total value of $20,000. This transaction involves othe
Edesa Biotech Shines at Autoimmune Conference
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Edesa Biotech Showcases Innovations at Healthcare Conference
Edesa Biotech to Participate in Barclays Global Healthcare Conference
TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today
Edesa Biotech Showcases Innovations at Dermatology Events
Edesa Biotech to Participate in Upcoming Dermatology Meetings
TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Edesa Biotech (EDSA) and Ocular Therapeutix (OCUL)
HC Wainwright & Co. Reiterates Buy on Edesa Biotech, Maintains $21 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Edesa Biotech with a Buy and maintains $21 price target.
Edesa Biotech GAAP EPS of -$0.54 Beats by $0.67
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced
CORRECTION: Edesa Biotech FY23 EPS $(2.93) Up From $(8.37) YoY
CORRECTION: Edesa Biotech FY23 EPS $(2.93) Up From $(8.37) YoY
Edesa Biotech Reports Fiscal Year 2023 Results
TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory di
Top Premarket Decliners
Global Water Resources (GWRS) shares tumbled 20% Wednesday premarket following a 1.4% gain in the previous session. Loop Media (LPTV) shares fell nearly 19% after the company reported lower fiscal Q4
PAVM, CCLD and EDSA Among Mid-day Movers
Edesa Biotech Is Maintained at Buy by HC Wainwright & Co.
Edesa Biotech Is Maintained at Buy by HC Wainwright & Co.
No Data